4th Obesity and Weight Loss Drug Development 2026

Memo

Advancing Personalized, Next-Generation Therapeutics to Redefine Metabolic Quality to Accelerate the Shift From Acute Weight Loss to Sustainable Disease Modification by Demonstrating Durable, Best-in-Class Therapeutic Impact. Welcome to the 4th Obesity and Weight Loss Drug Development Summit - the definitive industry-forum dedicated to redefining the standards of metabolic medicine by mastering precision treatment, preserving functional health, and navigating the high-stakes transition to next-generation oral and multi-agonist therapies. The obesity therapeutics market has entered a radical transformation. Driven by the unprecedented success of first-generation incretins, the landscape has reached a critical juncture where "simple weight loss" is no longer enough to win. As we move through 2026, the industry is under intense pressure to move beyond BMI-centric endpoints and unlock new levels of quality, targeting the 40% of adults globally who require more than a one-size-fits-all approach. The race is now on to decouple adipose reduction from skeletal muscle atrophy and secure long-term adherence through needle-free, scalable solutions that promise to transform chronic disease management forever. The 4th Obesity and Weight Loss Drug Development Summit stands as the essential global forum for experts dedicated to accelerating this vital progress. This year, we are diving deep into the game-changing potential of multi-targeted portfolios, novel biological pathways and new modalities for a precision medicine approach, alongside the "Oral-First" revolution. Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly, and Merck and Co., as well as innovative biotechs such as Veru Inc., Canary Cure, and Metsera, who will share their ground-breaking research on preserving lean mass and preventing post-treatment weight regain. Don't miss this pivotal opportunity to network with 120+ leading experts in the field of advanced obesity therapeutics. Forge crucial collaborations and be part of the solution that will define the 2026 pipeline.     URLs:Tickets: https://go.evvnt.com/3514489-2?pid=5569 Brochure: https://go.evvnt.com/3514489-3?pid=5569    Date and Time: Tue, 14 Jul 2026 09:00 - Thu, 16 Jul 2026 17:00   Venue details: Hotel Commonwealth, 500 Commonwealth Avenue, Boston, Massachusetts, 02215, United States    Prices:Drug Developer Pricing - Conference + 2 Workshops: USD 3597.00,Drug Developer Pricing - Conference + 1 Workshop: USD 3148.00,Drug Developer Pricing - Conference Only: USD 2699.00,Academic Pricing - Conference + 2 Workshops: USD 2997.00,Academic Pricing - Conference + 1 Workshop: USD 2648.00,Academic Pricing - Conference Only: USD 2299.00,Service Provider Pricing - Conference + 2 Workshops: USD 5397.00,Service Provider Pricing - Conference + 1 Workshop: USD 4648.00,Service Provider Pricing - Conference Only: USD 3899.00 Speakers: Kalev Kask, Chief Executive Officer, Adge Pharmaceuticals Inc., Raj Reddy, Chief Executive Officer, Canary Cure, Michael Lincoff, Chief Clinical Officer, Canary Cure and Ex Chair, Cardiovascular and Renal Drugs Advisory Committee, Canary Cure Therapeutics, Mina Sooch, Strategic Adviser, Cirius Therapeutics, Roman Cailleteau, Chief Medical Officer, CORXEL Pharmaceuticals, Iris Grossman, Chief Therapeutics Officer, Eleven Therapeutics, Adi Gilboa-Geffen, Chief Technology Officer, Eleven Therapeutics, Kenneth Attie, Vice Presiden- Clinical Research and Obesity, Eli Lilly and Co., Olivier Boss, Chief Scientific Officer and Founder, Energesis Pharmaceuticals Inc, Haleema Qamar, Research Scientist, Merck and Co, Janhavi Dalvi, Neonatologist, New York University, Hong Chen, Director - Evaluation and Search, Novo Nordisk, Chien Li, Associate Director, Novo Nordisk, Ann Belien, Founder and Chief Executive Officer, Rejuvenate Biomed, Linda Sasset, Senior Scientist, RenBio, Harshini Neelakantan, Executive Director - Research and Development, Ridgeline Therapeutics, Dan Oieru, Medical Director, Lead Cardiovascular Renal Metabolics, Product Development Roche Genentech, Roche, Cuauhtemoc Licona, Chief Scientific Officer, SciTherm Therapeutics, Philip Larsen, CEO, Six Peaks Bio, David Rosenbaum, Chief Development Officer, Syntis Bio, Shreya Singh, Associate Scientist, Transpire Bio, Simon Bailey, Chief Operating Officer and President - Research and Development, Unnatural Products Inc., Mitchell Steiner, CEO, Veru Inc., Gary Barnette, Chief Scientific Officer, Veru Inc.